Hookipa Pharma has announced a collaboration with Roche for the development and commercialisation of HB-700, a new investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers. The deal, which is worth up to US$958 M, will provide Roche with an opportunity to strengthen its oncology franchise. This alliance marks the first oncology licensing deal for Hookipa, granting validation for its multi-KRAS approach.